drugset / Trial / NCT07117890
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Timeline
- Start
- 2025-02-07
- Primary completion
- 2027-02-20
- Completion
- 2027-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunvozertinib | Small molecule | 200 mg | — |
| Subject | Sunvozertinib | Small molecule | 300 mg | — |